Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058053 | 0.78 | CTSL (0.43) | CTSLCTSBCTSKNAAALMNA | |
| SCHEMBL15927873 | 0.75 | CTSL (0.51) | CTSLCTSBCTSKNAAALMNA | |
| SCHEMBL15927872 | 0.75 | CTSL (0.51) | CTSLCTSBCTSKNAAALMNA | |
| SCHEMBL1613917 | 0.70 | TSHR (0.48) | CTSLCTSBCTSKNAAALMNA | |
| SCHEMBL9394261 | 0.70 | TSHR (0.48) | CTSLCTSBCTSKNAAALMNA | |
| SCHEMBL2701945 | 0.69 | CTSL (0.53) | CTSLCTSBCTSKNAAA | |
| SCHEMBL4031096 | 0.69 | OPRM1 (0.58) | — | |
| SCHEMBL9813742 | 0.68 | CTSL (0.46) | CTSLCTSBCTSKNAAALMNA | |
| Hydrochloric Acid SCHEMBL30384626 | 0.68 | CTSL (0.51) | CTSLCTSBCTSKNAAA | |
| SCHEMBL6858811 | 0.68 | CTSK (1.00) | CTSLCTSBCTSKNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | GRIA1, GLRA1, GRIN1 | CTSL 3860/4885CTSB 2577/4885CTSK 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.